Shanghai Fosun Pharmaceutical (02196): The drug registration application for the injection of bromohexine hydrochloride has been accepted.

Shanghai Fosun Pharmaceutical (02196) announced that its holding subsidiary Chongqing Yaoyou Pharmaceutical Co., Ltd. recently had its drug registration application for the injection of Bromhexine Hydrochloride accepted by the National Medical Products Administration. The injection of Bromhexine Hydrochloride is a chemical drug independently developed by the group (the company and its holding subsidiaries/units). The drug is intended for the treatment of phlegm in the following diseases and symptoms in cases where oral administration is difficult: pulmonary tuberculosis, pneumoconiosis, and postoperative conditions. As of January 2025, the group has invested approximately RMB 1.64 million (unaudited) in research and development of the injection of Bromhexine Hydrochloride. According to the latest data from IQVIA CHPA, the sales of the injection of Bromhexine Hydrochloride in China (excluding Hong Kong, Macau, and Taiwan) were approximately RMB 1.589 billion in 2023.